Reprogramming of liver to pancreas.
Islet grafts have demonstrated that patients with diabetes would benefit greatly by beta-cell therapy. However, the paucity of available islets for transplantation as well as the immunological barriers faced in allogeneic transplantation represent a tremendous barrier to regenerative approaches to the treatment of diabetes. Here, we present a strategy and protocols to transdifferentiate developmentally related hepatocytes into beta-cells by the ectopic expression of critical beta-cell transcription factors.
Thowfeequ
Shifaan
S
Centre for Regenerative Medicine, Department of Biology, University of Bath, Bath, UK.
Li
Wan-Chun
WC
Slack
Jonathan M W
JM
Tosh
David
D
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D002460:Cell Line; D002469:Cell Separation; D002478:Cells, Cultured; D065150:Cellular Reprogramming; D005455:Fluorescent Antibody Technique; D005786:Gene Expression Regulation; D022781:Hepatocytes / Q000166:cytology / Q000378:metabolism / Q000821:virology; D006801:Humans; D008099:Liver / Q000166:cytology / Q000378:metabolism*; D010179:Pancreas / Q000166:cytology / Q000378:metabolism*; D051381:Rats; D020133:Reverse Transcriptase Polymerase Chain Reaction; D023822:Tissue Engineering / Q000379:methods*; D014162:Transfection